Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.46 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.46 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27512904 | 0.81 | SKP2 (0.39) | SKP2CYP3A4CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL23092965 | 0.77 | SKP2 (0.58) | SKP2CYP3A4CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL16079449 | 0.74 | CYP3A4 (0.47) | SKP2CYP3A4CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL16083945 | 0.74 | CYP3A4 (0.47) | SKP2CYP3A4CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL23114374 | 0.73 | SKP2 (0.49) | SKP2CYP3A4CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL11419062 | 0.71 | SKP2 (0.43) | SKP2CYP3A4CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL5838115 | 0.70 | SKP2 (0.68) | SKP2CYP3A4CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL23093089 | 0.70 | SKP2 (0.42) | SKP2CYP3A4CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL2475751 | 0.70 | NPC1 (0.62) | SKP2CYP3A4CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL1004694 | 0.70 | NPC1 (0.68) | SKP2CYP3A4CYP2D6CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9511072-B2 | Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2016-12-06 | — | — | US | claimed |
| US-20140329811-A1 | Methods of Modulating Cell Proliferation and Cyst Formation in Polycystic Kidney and Liver Diseases | MCW RESEARCH FOUNDATION, INC. | 2014-11-06 | — | — | US | claimed |
| US-7307101-B2 | Use of 20-HETE synthesizing enzyme inhibitors as therapy for cerebral vascular disease | MCW RESEARCH FOUNDATION, INC. (US) | 2007-12-11 | — | — | US | claimed |
| EP-1682153-A2 | METHODS OF MODULATING ANGIOGENESIS AND CANCER CELL PROLIFERATION | MCW Research Foundation, Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005046658-A2 | METHODS OF MODULATING ANGIOGENESIS AND CANCER CELL PROLIFERATION | MCW RESEARCH FOUNDATION, INC. (US) | 2005-05-26 | — | — | WO | claimed |
| EP-2061450-B1 | METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES | MEDICAL COLLEGE WISCONSIN INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9511072-B2 | Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| CN-105492011-A | Therapeutic synergy of undesirable chemical compounds | BROWN DENNIS M | 2016-04-13 | — | — | CN | disclosed |
| CN-104797267-A | Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof | DEL MAR PHARMACEUTICALS | 2015-07-22 | — | — | CN | disclosed |
| US-20140329811-A1 | Methods of Modulating Cell Proliferation and Cyst Formation in Polycystic Kidney and Liver Diseases | MCW RESEARCH FOUNDATION, INC. | 2014-11-06 | — | — | US | disclosed |
| EP-2061450-A2 | METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES | MCW Research Foundation, Incorporated (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080167382-A1 | By administering a 20-hydroxyeicosatetraenoic acid (20-HETE) synthesizing enzyme inhibitor or a 20-HETE antagonist; antiproliferative agents | THE MEDICAL COLLEGE OF WISCONSIN, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008034011-A2 | METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES | MCW RESEARCH FOUNDATION, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1682153-A2 | METHODS OF MODULATING ANGIOGENESIS AND CANCER CELL PROLIFERATION | MCW Research Foundation, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050124618-A1 | Methods of modulating angiogenesis and cancer cell proliferation | HENRY FORD HEALTH SYSTEM | 2005-06-09 | — | — | US | disclosed |
| WO-2005046658-A2 | METHODS OF MODULATING ANGIOGENESIS AND CANCER CELL PROLIFERATION | MCW RESEARCH FOUNDATION, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329811-A1 | Methods of Modulating Cell Proliferation and Cyst Formation in Polycystic Kidney and Liver Diseases | PKD1, PKD2, ALOX15 | SKP2 642/4885CYP3A4 3098/4885CYP2D6 2147/4885 |
| US-20080167382-A1 | By administering a 20-hydroxyeicosatetraenoic acid (20-HETE) synthesizing enzyme inhibitor or a 20-HETE antagonist; antiproliferative agents | PKD1, PKD2, ALOX15 | SKP2 736/4885CYP3A4 2013/4885CYP2D6 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.